Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma

Pediatrics

Volumn 131, Issue 1, 2013, Pages

  Krishnadas, Deepa Kolaseri ^a   Shapiro, Teresa ^a   Lucas, Kenneth ^a  

^a PENN STATE CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer testis antigens; Decitabine; MAGE A1; MAGE A3; Neuroblastoma; NY ESO 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKALINE PHOSPHATASE; CANCER TESTIS ANTIGEN; CARBOPLATIN; DENDRITIC CELL VACCINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOMODULATING AGENT; IRINOTECAN; ISOTRETINOIN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELPHALAN; MONOCLONAL ANTIBODY CH14.18; NY ESO 1 ANTIGEN; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL MASS; ABDOMINAL TUMOR; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; BONE EXAMINATION; BONE MARROW BIOPSY; BONE MARROW TUMOR; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CELL COUNT; CELL INFILTRATION; CHILD; DEMETHYLATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INDUCTION CHEMOTHERAPY; LIVER TOXICITY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; UPREGULATION;

EID: 84872863162     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0376     Document Type: Article

References (29)

1. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-216
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202-2211
3. Yu AL, Gilman AL, Ozkaynak MF, et al Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334
4. Gross N, Beck D, Favre S. In vitro modulation and relationship between N-myc and HLA class I RNA steady-state levels in human neuroblastoma cells. Cancer Res. 1990;50(23):7532-7536
5. Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P. Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer. 1993;55(5):817-823
6. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94(5):1914-1918
7. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337-365
8. Wölfl M, Jungbluth AA, Garrido F, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54(4):400-406
9. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer. 2001;1(3):194-202
10. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-29-deoxycytidine with valproic acid. Leuk Res. 2005;29(7):739-748
11. Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating agents. Semin Hematol. 2005;42(3 suppl 2): S50-S59
12. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23(17):3948-3956
13. Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-29-deoxycytidine upregulates the expression of cancertestis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. 2009;58(4): 589-601
14. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12(19):5777-5785
15. Bao L, Dunham K, Lucas K. MAGE-A1, MAGEA3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011;60(9): 1299-1307
16. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005;174(5):3080-3086
17. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000;86(3):385-392
18. Bender A, Karbach J, Neumann A, et al. LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007;7:16
19. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA. 2004;101(29):10697-10702
20. Ploegh HL. Viral strategies of immune evasion. Science. 1998;280(5361):248-253
21. Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-29-deoxycytidine treatment. Int J Cancer. 2001;94(2):243-251
22. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44(12 pt 1):5914-5920
23. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47(4):1098-1104
24. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23): 6050-6056
25. Caruso DA, Orme LM, Amor GM, et al. Results of a Phase I study utilizing monocytederived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer. 2005;103(6):1280-1291
26. Russell HV, Strother D, Mei Z, et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008;31(9):812-819
27. Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007;30(2):227-233
28. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6(5):529-535
29. George RE, Lahti JM, Adamson PC, et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 2010;55(4):629-638